Article

Pembrolizumab alters the tumor immune landscape in a patient with dMMR glioblastoma

2023-12-26

Abstract excerpt

Congenital DNA mismatch repair defects (dMMR), such as Lynch Syndrome, predispose patients to a variety of cancers and account for approximately 1% of glioblastoma cases. While few therapeutic options exist for glioblastoma, checkpoint blockade therapy has proven effective in dMMR tumors. Here we present a case study of a male in their 30s diagnosed with dMMR glioblastoma treated with pembrolizumab who experienced...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 88ed76d5-9c9f-536b-982d-e14ee1507014
DOI: 10.1101/2023.12.08.23299732

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Pembrolizumab alters the tumor immune landscape in a patient with dMMR glioblastomaDOI 10.1101/2023.12.08.23299732Read

High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.Semantic proximity Read

Clinicopathologic, molecular and tumor immune microenvironment features of mismatch repair-deficient glioblastomas in Lynch syndrome: a multicenter study of 29 cases with therapeutic implications.Semantic proximity Read

Pembrolizumab in MSI-H–dMMR Advanced Colorectal Cancer — A New Standard of CareSemantic proximity Read

"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade.Semantic proximity Read

Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy.Semantic proximity Read

Immunoprofiles of colorectal cancer from Lynch syndromeSemantic proximity Read

Integrating spatial profiles and cancer genomics to identify immune-infiltrated mismatch repair proficient colorectal cancersSemantic proximity Read

Response to immune checkpoint inhibition in a meningioma with DNA mismatch repair deficiencySemantic proximity Read

Biomarker study of pembrolizumab in patients with advanced rare cancers.Semantic proximity Read

Treatment with checkpoint inhibitors in a metastatic colorectal cancer patient with molecular and immunohistochemical heterogeneity in MSI/dMMR statusSemantic proximity Read

Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study.Semantic proximity Read

Immunological profiles in Lynch syndrome colorectal cancers are not specific to mismatch repair gene defectsSemantic proximity Read